OncoMatch/Clinical Trials/NCT06768931
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Is NCT06768931 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Required: ESR1 ≤10% expression (≤10%)
ER≤10%
Required: PR (PGR) ≤10% expression (≤10%)
PR≤10%
Required: HER2 (ERBB2) negative (negative)
HER-2 negative
Required: PD-L1 (CD274) expression testing required
tumor specimens ... available for PD-L1 expression testing
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: for advanced breast cancer
Patients must not have received chemotherapy or targeted therapy for advanced breast cancer
Cannot have received: targeted therapy
Exception: for advanced breast cancer
Patients must not have received chemotherapy or targeted therapy for advanced breast cancer
Cannot have received: immune checkpoint inhibitor
Previous treatment with immune checkpoint inhibitors
Lab requirements
Blood counts
anc≥1.5×10^9/l, plt≥75×10^9/l, hb≥90g/l (no blood transfusions or blood products within 14 days, and no use of g-csf or other hematopoietic growth factors for correction)
Kidney function
bun and cr≤1×uln or endogenous creatinine clearance ≥50ml/min (cockcroft-gault formula)
Liver function
tbil<1.5×uln, alt, ast<2.5×uln, for patients with liver metastasis, alt, ast may be <5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06768931 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ESR1?
Yes, ESR1 ≤10% expression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR ≤10% expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB or IIIC is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify